80% Of Cerezyme Patients Have Returned Since Shipments Resumed, Genzyme Says

At J.P. Morgan conference, CEO Termeer says manufacturing problems are in the past and priorities include building redundant capacity to avoid any future shortages.

More from Archive

More from Pink Sheet